ABVC Biopharma Ownership
| ABVC Stock | USD 0.53 0.02 3.92% |
Shares in Circulation | First Issued 2002-06-30 | Previous Quarter 11.3 M | Current Value 12.4 M | Avarage Shares Outstanding 3.3 M | Quarterly Volatility 13 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ABVC |
ABVC Stock Ownership Analysis
About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. ABVC Biopharma recorded a loss per share of 0.81. The entity last dividend was issued on the 8th of May 2019. The firm had 1:10 split on the 25th of July 2023. ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on ABVC Biopharma please contact Howard MD at (510)-668-0881 or go to https://www.abvcpharma.com.Besides selling stocks to institutional investors, ABVC Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ABVC Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ABVC Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ABVC Biopharma Quarterly Liabilities And Stockholders Equity |
|
About 23.0% of ABVC Biopharma are currently held by insiders. Unlike ABVC Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ABVC Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ABVC Biopharma's insider trades
ABVC Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ABVC Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ABVC Biopharma backward and forwards among themselves. ABVC Biopharma's institutional investor refers to the entity that pools money to purchase ABVC Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Chase Investment Counsel Corp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 71.6 K | Vanguard Group Inc | 2024-09-30 | 46.9 K | Honkamp Krueger Financial Services Inc | 2024-09-30 | 39 K | Xtx Topco Ltd | 2024-09-30 | 23.4 K | Northern Trust Corp | 2024-09-30 | 19.1 K | State Street Corp | 2024-09-30 | 12.9 K | Two Sigma Securities, Llc | 2024-09-30 | 12.4 K | Tower Research Capital Llc | 2024-09-30 | 2.6 K |
ABVC Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ABVC Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ABVC Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ABVC Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ABVC Biopharma Outstanding Bonds
ABVC Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ABVC Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ABVC bonds can be classified according to their maturity, which is the date when ABVC Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share 0.017 | Quarterly Revenue Growth 18.175 | Return On Assets (0.45) | Return On Equity (3.20) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.